A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

R. Gilbert, Mark; J. Dignam, James; S. Armstrong, Terri; S. Wefel, Jeffrey; T. Blumenthal, Deborah; A. Vogelbaum, Michael; Colman, Howard; Chakravarti, Arnab; L. Pugh, Stephanie; Won, Minhee; Jeraj, Robert; D. Brown, Paul; A. Jaeckle, Kurt; Schiff, David; W. Stieber, Volker; Brachman, David; Werner‐Wasik, Maria; W. Tremont‐Lukats, Ivo; P. Sulman, Erik; Aldape, Kenneth; J. Curran, Walter; P. Mehta, Minesh

doi:10.1056/nejmoa1308573

Public

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

Published in New England Journal of Medicine • Feb 19, 2014

Authors:

Mark R. Gilbert

James J. Dignam

Terri S. Armstrong

Abstract

BACKGROUND: Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurr...

Subject

Bevacizumab

Temozolomide

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!